Is URINARY TRACT INFECTION a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed URINARY TRACT INFECTION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 18 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported URINARY TRACT INFECTION to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and URINARY TRACT INFECTION. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause URINARY TRACT INFECTION, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes URINARY TRACT INFECTION. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if URINARY TRACT INFECTION ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing URINARY TRACT INFECTION: 18
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where URINARY TRACT INFECTION is a reported side effect: 0.5407%

FDA reports of any drug causing URINARY TRACT INFECTION : 42137
Average percentage for all medicated patients where URINARY TRACT INFECTION is reported as a complication: 0.2641%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with URINARY TRACT INFECTION:

FOSAMAX (7395 patients)
TYSABRI (5233 patients)
ASPIRIN (4175 patients)
VIOXX (3973 patients)
AVONEX (3813 patients)
PREDNISONE (2490 patients)
HUMIRA (2313 patients)
LASIX (2144 patients)
ZOMETA (1825 patients)
ENBREL (1734 patients)
OMEPRAZOLE (1666 patients)
METHOTREXATE (1620 patients)
FOLIC ACID (1609 patients)
LIPITOR (1606 patients)
SEROQUEL (1593 patients)
SYNTHROID (1546 patients)
LISINOPRIL (1545 patients)
COUMADIN (1509 patients)
FUROSEMIDE (1498 patients)
REBIF (1483 patients)
NEXIUM (1473 patients)
REMICADE (1439 patients)
FORTEO (1410 patients)
PREDNISOLONE (1352 patients)
NEURONTIN (1323 patients)
PRILOSEC (1313 patients)
ACETAMINOPHEN (1268 patients)
ATENOLOL (1240 patients)
SIMVASTATIN (1234 patients)
DIGOXIN (1231 patients)
AMBIEN (1205 patients)
HEPARIN SODIUM INJECTION (1188 patients)
PROTONIX (1185 patients)
AREDIA (1148 patients)
ZOLOFT (1110 patients)
POTASSIUM CHLORIDE (1100 patients)
LEVOTHYROXINE SODIUM (1073 patients)
ZOCOR (1064 patients)
BACLOFEN (1040 patients)
LEVAQUIN (1033 patients)
XANAX (1020 patients)
PLAVIX (1018 patients)
NORVASC (1018 patients)
HYDROCHLOROTHIAZIDE (1009 patients)
VITAMIN D (1006 patients)
CLOZARIL (998 patients)
ALBUTEROL (978 patients)
LYRICA (961 patients)
PREVACID (954 patients)
TOPROL-XL (895 patients)
VICODIN (895 patients)
CELEBREX (888 patients)
REVLIMID (887 patients)
PREMARIN (876 patients)
PREDNISONE TAB (867 patients)
ATIVAN (863 patients)
DEXAMETHASONE (855 patients)
LORAZEPAM (851 patients)
ALENDRONATE SODIUM (838 patients)
LEXAPRO (834 patients)
METFORMIN HCL (823 patients)
MYCOPHENOLATE MOFETIL (812 patients)
OXYCONTIN (802 patients)
GABAPENTIN (802 patients)
CYMBALTA (786 patients)
DIOVAN (785 patients)
CALCIUM (780 patients)
IBUPROFEN (780 patients)
CIPROFLOXACIN (764 patients)
ZOFRAN (746 patients)
PERCOCET (729 patients)
LANTUS (716 patients)
ZYPREXA (712 patients)
PAXIL (683 patients)
PROZAC (667 patients)
METOPROLOL TARTRATE (664 patients)
WARFARIN SODIUM (633 patients)
RISPERDAL (633 patients)
MORPHINE (631 patients)
MULTI-VITAMIN (631 patients)
SPIRIVA (629 patients)
OXYCODONE HCL (625 patients)
MULTI-VITAMINS (624 patients)
ALLOPURINOL (622 patients)
ALPRAZOLAM (618 patients)
NITROGLYCERIN (616 patients)
AMLODIPINE (612 patients)
INSULIN (612 patients)
FOSAMAX PLUS D (612 patients)
CIPRO (611 patients)
CLONAZEPAM (609 patients)
BYETTA (578 patients)
CALCIUM CARBONATE (577 patients)
LOVENOX (574 patients)
ACCUTANE (564 patients)
COLACE (563 patients)
LORTAB (561 patients)
CYCLOSPORINE (560 patients)
ACTONEL (557 patients)
DIAZEPAM (557 patients)
AMOXICILLIN (556 patients)
EFFEXOR (555 patients)
BETASERON (551 patients)
ASCORBIC ACID (550 patients)
EXJADE (545 patients)
ADVAIR DISKUS 100/50 (544 patients)
SOLIRIS (543 patients)
COREG (541 patients)
FERROUS SULFATE TAB (541 patients)
DECADRON (525 patients)
KLONOPIN (524 patients)
GLUCOPHAGE (516 patients)
ZANTAC (514 patients)
TYLENOL (CAPLET) (513 patients)
CRESTOR (513 patients)
COMPAZINE (512 patients)
FENTANYL (512 patients)
CLOZAPINE (512 patients)
REGLAN (510 patients)
TYLENOL (506 patients)
TACROLIMUS (502 patients)
TRAMADOL HCL (501 patients)
SPIRONOLACTONE (501 patients)
CELEXA (495 patients)
SINGULAIR (488 patients)
NAPROXEN (488 patients)
CALCIUM (UNSPECIFIED) (487 patients)
TRAZODONE HCL (476 patients)
NAMENDA (474 patients)
PANTOPRAZOLE (472 patients)
ALLEGRA (467 patients)
DURAGESIC-100 (467 patients)
FLEXERIL (464 patients)
SANDOSTATIN LAR (464 patients)
PEPCID (461 patients)
BACTRIM (457 patients)
ARANESP (457 patients)
FLOMAX (456 patients)
COZAAR (450 patients)
KEPPRA (445 patients)
LANSOPRAZOLE (441 patients)
ENALAPRIL MALEATE (440 patients)
LOPRESSOR (438 patients)
RAMIPRIL (435 patients)
NUVARING (433 patients)
VITAMIN E (427 patients)
NEORAL (424 patients)
DILAUDID (423 patients)
METOPROLOL (420 patients)
VELCADE (415 patients)
CEPHALEXIN (412 patients)
RANITIDINE (412 patients)
BONIVA (409 patients)
ZYRTEC (404 patients)
CLONIDINE (397 patients)
ALDACTONE (395 patients)
VITAMIN B-12 (393 patients)
WELLBUTRIN (392 patients)
EXELON (392 patients)
ELAVIL (390 patients)
AMITRIPTYLINE HCL (389 patients)
METOCLOPRAMIDE (388 patients)
FEMARA (386 patients)
BENADRYL (384 patients)
CARBOPLATIN (383 patients)
VITAMINS (UNSPECIFIED) (383 patients)
DIANEAL (378 patients)
ZETIA (377 patients)
CYCLOPHOSPHAMIDE (377 patients)
ACTOS (375 patients)
NYSTATIN (374 patients)
PROMETHAZINE (374 patients)
CITALOPRAM HYDROBROMIDE (374 patients)
GLIPIZIDE (372 patients)
GILENYA (368 patients)
ARICEPT (368 patients)
VALIUM (366 patients)
MORPHINE SULFATE (366 patients)
[THERAPY UNSPECIFIED] (365 patients)
TAMOXIFEN CITRATE (363 patients)
ZITHROMAX (362 patients)
MIRALAX (361 patients)
ULTRAM (359 patients)
HEPARIN (352 patients)
MOTRIN (352 patients)
MACROBID (351 patients)
KEFLEX (350 patients)
IRON (350 patients)
LACTULOSE (349 patients)
CHEMOTHERAPEUTICS NOS (348 patients)
ALTACE (346 patients)
METFORMIN (346 patients)
CLARITIN (346 patients)
CISPLATIN (345 patients)
ARIMIDEX (343 patients)
CLINDAMYCIN (337 patients)
CARVEDILOL (336 patients)
AUGMENTIN '125' (333 patients)
HUMALOG (333 patients)
MIRTAZAPINE (332 patients)
FLUCONAZOLE (332 patients)
PHENERGAN (330 patients)
METOPROLOL SUCCINATE (329 patients)
DEPAKOTE (328 patients)
MIRENA (328 patients)
GLYBURIDE (325 patients)
POTASSIUM (325 patients)
FAMOTIDINE (324 patients)
TAXOTERE (322 patients)
TAXOL (316 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about URINARY TRACT INFECTION and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.